AstraZeneca PLC (AZN)
| Market Cap | 196.63B |
| Revenue (ttm) | 51.21B |
| Net Income (ttm) | 6.50B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.15 |
| PE Ratio | 30.27 |
| Forward PE | 13.75 |
| Dividend | $1.48 (2.31%) |
| Ex-Dividend Date | Aug 9, 2024 |
| Volume | 7,658,136 |
| Open | 63.89 |
| Previous Close | 63.20 |
| Day's Range | 63.53 - 64.34 |
| 52-Week Range | 60.47 - 87.68 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 88.80 (+38.19%) |
| Earnings Date | Nov 12, 2024 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $88.8, which is an increase of 38.19% from the latest price.
News
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improv...
RFK Jr.'s HHS nomination sparks concern over pharma stocks
President-elect Trump's decision to nominate Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS) has sparked concerns, particularly about his skepticism toward the pharmaceutical...
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
MENLO PARK, Calif. , Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patien...
Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC
Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer driver mutations SEOUL, South Korea , Nov. 18, 2024 /PRNewswire/ -- Lunit (KRX...
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme...
Pharma shares hit as Trump picks RFK Jr to lead health department
Choice of vaccine critic knocks some of world's biggest drugmakers including Moderna, AstraZeneca and GSK
Bullish Opportunities in AZN
Tony Zhang with @OptionsPlay says AstraZeneca (AZN) has more going for it than its stock chart may show. Following the company's latest earnings, he points to strength in key metrics as a sign for bul...
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
AstraZeneca PLC aims for $80 billion revenue by 2030, driven by strong growth in oncology, biopharmaceuticals, and rare diseases, despite recent share price declines. The company's weight management p...
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to purchase Summa Health for $485 million.
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Executive Director and CEO Arad...
AstraZeneca Lifts Outlook, Plans $3.5B US Investment
British drugmaker AstraZeneca (AZN) increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the ...
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
AstraZeneca Plc AZN reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion.
AstraZeneca: 450 million pound investment in UK under review amid talks with govt
London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, announced in March, is under review while talks with th...
AstraZeneca says detained China head has lawyer, but company still in dark
AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but the company has very little information about the case, its CEO said on Tuesd...
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company's research and manufacturing footprint by the ...
AstraZeneca's 9M and Q3 2024 results
CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary 9M 2024 % Change Q3 2024 % Change $m Actual CER1 $m Actual CER - Product Sales 37,576 16 19 12,947 18 20 - Alliance...
AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time in less than four months on Tuesday, helped by resilient demand for its cancer and rare diseases medicines, after ...
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have submitted a new Biologics License Application (BLA) for accelerated approval in the ...
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here's how Americans voted on abortion access.
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product.
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZene...
AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)
AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy the stock as the big picture looks positive. The company's numbers were strong in H1 2024 and its earn...
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in hematology at the 66th American Society o...
China Has Detained a Senior AstraZeneca Executive
Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese government is probing AstraZeneca employees, the drugmaker says.